Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRE | P78334 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067260 | 0.84 | MAPK14 (0.40) | MAPTNPC1L3MBTL1PTGESJAK2 | |
| SCHEMBL10067283 | 0.82 | HRH4 (0.38) | — | |
| SCHEMBL10067311 | 0.80 | MEN1 (0.46) | KDM4EMAPTNPC1GAAALDH1A1 | |
| SCHEMBL22200839 | 0.78 | NPY5R (0.51) | KDM4EMAPTL3MBTL1GABRPGABRD | |
| SCHEMBL10067256 | 0.75 | MEN1 (0.56) | KDM4EMAPTGAAALDH1A1MEN1 | |
| SCHEMBL10067277 | 0.75 | LMNA (0.50) | KDM4EMAPTL3MBTL1ALDH1A1GLA | |
| SCHEMBL14023648 | 0.75 | KMT2A (0.39) | KDM4EMAPTNPC1PTGESJAK2 | |
| SCHEMBL10067295 | 0.75 | LMNA (0.49) | KDM4EMAPTL3MBTL1ALDH1A1GLA | |
| SCHEMBL10067281 | 0.75 | LMNA (0.49) | KDM4EMAPTL3MBTL1ALDH1A1GLA | |
| SCHEMBL10067265 | 0.75 | MAPK14 (0.43) | KDM4EMAPTNPC1PTGESJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| US-8148392-B2 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer | LORUS THERAPEUTICS INC. (CA) | 2012-04-03 | — | — | US | disclosed |
| WO-2010102393-A1 | 2-INDOLYL IMIDAZO [4,5-D]PHENANTHROLINE DERIVATIVES AND THEIR USE TO INHIBIT ANGIOGENESIS | LORUS THERAPEUTICS INC. (CA) | 2010-09-16 | — | — | WO | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | APTOSE BIOSCIENCES INC. (CA) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168417-A1 | 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer | FLI1, IKZF3, IKZF2 | KDM4E 155/4885MAPT 4513/4885NPC1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.